Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

99.72 -1.17 (-1.16%)
Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
With yields between 3.4% and 6.8%, you'll need to think carefully about the highest yields in the Dow before you buy them. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy? ↗
After a long hiatus, why are the bulls so willing to buy in now? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Do These 3 Healthcare Stocks Need a Checkup? ↗
These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗
The healthcare stock could skyrocket if ivonescimab obtains approval from regulators, but there's still plenty of risk here. 
Via The Motley Fool
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗
Via Stocktwits
Topics Workforce
News headline image
Is This Pharmaceutical Giant a Buy After a Major Acquisition? ↗
The rebound is well underway. 
Via The Motley Fool
Topics Death
News headline image
These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them? ↗
After tepid performances throughout most of 2025, these stocks are showing some upward momentum. 
Via The Motley Fool
Topics Stocks
News headline image
With Netflix's 10-for-1 Stock Split Complete, Here Are 3 Growth Stocks to Buy in December That Could Issue Stock Splits in 2026 ↗
Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new year. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
3 Top ETFs I Plan to Pile Into in December to Boost My Passive Income in 2026 ↗
These ETFs can provide me with lots of passive income. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,... 
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
Wall Street's Tentative Triumph: Dow, S&P 500, Nasdaq Edge Higher Amidst Shifting Tides
Wall Street has recently concluded a tumultuous yet ultimately resilient period, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all managing to edge higher in late November and... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
2 Monster Stocks in the Making to Buy and Hold ↗
There's still time to get in on these rising stars. 
Via The Motley Fool
News headline image
1 Value Stock to Target This Week and 2 We Question
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
Global Markets Brace as Treasury Yields Surge Amidst BOJ Speculation and Risk Aversion
As December 1, 2025, dawns, global financial markets are grappling with a significant uptick in Treasury yields, a movement primarily catalyzed by a substantial sell-off in Japanese government debt and... 
Via MarketMinute
Topics Bonds Economy Stocks
News headline image
Treasury Yields Surge Amid Global Shifts and Fiscal Concerns: A Deep Dive into Market Implications
New York, NY – December 1, 2025 – U.S. Treasury yields have experienced a significant climb today, marking a pivotal moment for financial markets. This ascent, driven by a complex interplay of global... 
Via MarketMinute
Topics Bonds Credit Cards Economy
News headline image
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders ↗
If you are thinking in decades and not days, this trio of dividend stocks could be the perfect starting point for your fledgling portfolio. 
Via The Motley Fool
Topics Energy Intellectual Property
News headline image
3 Non-AI Stocks to Buy: MRK, UPS, CVX ↗
There are plenty of potential winners outside the world of AI. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%? ↗
The struggling pharmaceutical giant is showing signs of life. 
Via The Motley Fool
News headline image
Dow Industrials Erase November Losses: A Beacon of Optimism Amidst Market Crossroads
The Dow Jones Industrial Average (DJIA) has staged a remarkable comeback, successfully erasing its November 2025 losses by the month's final trading day, Friday, November 28, 2025. This significant... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Merck & Co. Inc. (NYSE:MRK): A Dividend Stock with Strong Profitability and Financial Health ↗
Discover Merck (MRK), a top dividend stock with a 3.58% yield, strong growth history, and excellent profitability for reliable income. 
Via Chartmill
News headline image
Dow Jones Navigates Volatility Amidst AI Bubble Fears and Shifting Fed Expectations
The Dow Jones Industrial Average has been on a roller-coaster ride in November 2025, experiencing significant volatility and sending mixed signals across various sectors. While the index achieved a... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Stocks making big moves yesterday: Meta, Tenet Healthcare, Wynn Resorts, Elevance Health, and Merck
Check out the companies making headlines yesterday: 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Merck (MRK) Stock Is Trading Up Today
Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Q3 Earnings Outperformers: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy World Trade
News headline image
Goldman Sachs Just Delivered Bad News for U.S. Investors ... Sort Of. Here's What You Need to Know. ↗
The investment bank's analysts simply recognize how much has changed in just the past few years, and what that means for the near future. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? ↗
The pharmaceutical giant's post-Keytruda plans continue to take shape. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Shares in the biotech company have surged on news of a big pharma takeover. 
Via The Motley Fool
News headline image
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗
Via MarketBeat
News headline image
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment ↗
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.